BeiGene
BGNE
#900
Rank
โ‚น1.869 T
Marketcap
โ‚น16,602
Share price
1.17%
Change (1 day)
6.05%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeiGene (BGNE)

Revenue in 2024 (TTM): โ‚น257.93 Billion

According to BeiGene 's latest financial reports the company's current revenue (TTM ) is โ‚น261.56 Billion. In 2023 the company made a revenue of โ‚น204.69 Billion an increase over the revenue in the year 2022 that were of โ‚น117.16 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeiGene from 2015 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚น257.93 B26.01%
2023 โ‚น204.69 B74.7%
2022 โ‚น117.16 B33.83%
2021 โ‚น87.55 B287.58%
2020 โ‚น22.58 B-26.02%
2019 โ‚น30.53 B120.32%
2018 โ‚น13.86 B-8.94%
2017 โ‚น15.22 B20833.65%
2016 โ‚น72.71 M-87.59%
2015 โ‚น0.58 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚น19.09 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น60.51 B-76.87%๐Ÿ‡บ๐Ÿ‡ธ USA